Back
Compare AU
Compare DRUG vs. GGUS
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the Betashares Geared Us Eqty Ccy Hedged Complex ETF (GGUS). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | GGUS | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 73 | 300 |
Median incremental investment | $742.79 | $1,103.78 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,657.88 | $3,167.36 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | GGUS | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | GGUS.AX was created on 2015-08-17 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund provides investors with a simple way to obtain a cost-effective geared exposure to the returns of the U.S. sharemarket, hedged to Australian Dollars. |
Top 3 holdings | AUD - AUSTRALIA DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) CHF - SWISS FRANC (0 %) | ISHARES CORE S&P 500 ETF (231.10 %) AUD - AUSTRALIA DOLLAR (105.06 %) USD - UNITED STATES DOLLAR (-236.16 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | Other (83.88 %) Communication Services (16.12 %) |
Top 3 countries | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) | United States (99.47 %) Switzerland (0.25 %) China (0.11 %) |
Management fee | 0.57 % | 0.8 % |
Key Summary
DRUG | GGUS | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.8 % |
Price | $8.53 | $47.85 |
Size | $176.672 million | $347.221 million |
10Y return | N/A | 444.99 % |
Annual distribution yield (5Y) | 1.92 % | 2.26 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 18/08/2015 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | GGUS | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 73 | 300 |
Median incremental investment | $742.79 | $1,103.78 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,657.88 | $3,167.36 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | GGUS | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | GGUS |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |